SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form D/A - Notice of Exempt Offering of Securities: [Amend]
SEC Accession No. 0001524679-11-000003
Filing Date
2011-08-02
Accepted
2011-08-02 07:00:50
Documents
1
Effectiveness Date
2011-08-02
Items
Item 04: Rule 504(b)(1) (not (i), (ii) or (iii))
Item 04.1: Rule 504(b)(1)(i)
Item 04.2: Rule 504(b)(1)(ii)
Item 04.3: Rule 504(b)(1)(iii)
Item 05: Rule 505
Item 06: Rule 506
Item 46: Securities Act Section 4(6)

Document Format Files

Seq Description Document Type Size
1 primary_doc.html D/A  
1 primary_doc.xml D/A 5045
  Complete submission text file 0001524679-11-000003.txt   6330
Mailing Address 244 5TH AVENUE SUITE 1727 NEW YORK NY 10001
Business Address 244 5TH AVENUE SUITE 1727 NEW YORK NY 10001 5407600535
Immune Response BioPharma, Inc. (Filer) CIK: 0001524679 (see all company filings)

IRS No.: 452563204 | State of Incorp.: DE | Fiscal Year End: 1231
Type: D/A | Act: 33 | File No.: 021-163802 | Film No.: 111001988